trial
as of 2026-07-01Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
NCTId NCT00455702
at a glance
Phase 4 · Completed
Enrollment 38 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2007-04
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
38 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-07
Primary completion
2007-04
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
Massachusetts General HospitalLead Sponsor
Investigators
1
Donald C. Goff, M.D.Principal Investigator
Sites
1 total
Boston, United States
Facts & assertions
4 sourced
Enrollment
38
Phase
PHASE4
Primary Completion Date
2007-04
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
investigator
person